Abstract | OBJECTIVE: METHODS: Hemodynamically stable patients with acute uterine bleeding sufficient to justify immediate medical or surgical intervention were enrolled in an open-label, randomized trial comparing oral medroxyprogesterone acetate 20 mg and a monophasic combination OC containing 1 mg norethindrone and 35 mug of ethinyl estradiol, each administered three times per day. Doses were reduced after 1 week to 20 mg per day and one tablet per day for the next 3 weeks for the medroxyprogesterone acetate and OC groups, respectively. Following baseline assessment, patients completed daily treatment and symptom logs collected at 14 and 28 days after initiation of therapy. RESULTS: CONCLUSION: This randomized trial is limited by sample size but suggests that both regimens may be effective and reasonably well tolerated. CLINICAL TRIAL REGISTRATION: Current Clinical Trials (clinicaltrials.gov, www.clinicaltrials.gov) Identifier: NCT00350480 LEVEL OF EVIDENCE: II-1.
|
Authors | Malcolm G Munro, Nakia Mainor, Romie Basu, Mikael Brisinger, Lorena Barreda |
Journal | Obstetrics and gynecology
(Obstet Gynecol)
Vol. 108
Issue 4
Pg. 924-9
(Oct 2006)
ISSN: 0029-7844 [Print] United States |
PMID | 17012455
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Contraceptive Agents, Female
- Contraceptives, Oral, Combined
- Medroxyprogesterone Acetate
|
Topics |
- Adult
- Contraceptive Agents, Female
(administration & dosage)
- Contraceptives, Oral, Combined
(administration & dosage)
- Female
- Humans
- Medroxyprogesterone Acetate
(administration & dosage)
- Patient Satisfaction
- Patient Selection
- Uterine Hemorrhage
(drug therapy, surgery)
|